Used as a key intermediate in the synthesis of peptide-based pharmaceuticals, particularly in the development of protease inhibitors. Its structure allows for selective coupling in solid-phase peptide synthesis, making it valuable for creating chiral compounds with high enantiomeric purity. The fluorenylmethyloxycarbonyl (Fmoc) group provides easy protection and deprotection of the amine functionality, enabling stepwise assembly of complex peptides. Commonly employed in research settings for drug discovery targeting diseases such as HIV and hepatitis C.